Undesirable reactions are undesirable phenomena, for which a causal relationship with loperamide is to be proven on the basis of a comprehensive assessment of the available information on the undesirable phenomenon. In some cases, it is rather difficult to establish reliably the causal relationship between the administration of loperamide and the occurrence of the listed symptoms. In addition, because clinical trials are conducted under different conditions, the incidence of adverse reactions in clinical trials of one drug can not be directly compared with the incidence of adverse reactions in clinical studies of another drug and may not reflect the incidence of unwanted reactions in clinical practice.
According to clinical studies
Unwanted reactions observed in ≥1% of patients taking Imodium ® in acute diarrhea: headache, constipation, flatulence, nausea, vomiting.Undesirable reactions observed in <1% of patients taking Imodium ® in acute diarrhea: drowsiness, dizziness, headache, dry mouth, abdominal pain, nausea, vomiting, constipation, discomfort and bloating, upper abdominal pain, rash .
Undesirable reactions observed in ≥1% of patients taking Imodium ® in chronic diarrhea: dizziness, flatulence, constipation, nausea.
Undesirable reactions observed in <1% of patients taking Imodium ® in chronic diarrhea: headache, abdominal pain, dry mouth, abdominal discomfort, dyspepsia.
According to spontaneous reports of adverse reactions
The following undesirable reactions were classified as follows: very frequent (≥10 %), frequent (≥1%, but <10%), not frequent (≥0.1%, but <1%), rare (≥0.01%, but <0.1%) and very rare (<0.01%, including single messages).
Impaired immune system. Very rarely: reactions hypersensitivity, anaphylactic reactions, including anaphylactic shock, and anaphylactoid reactions.
Violations from the nervous system. Very rare: violation coordination, depression, hypertonus, loss of consciousness, drowsiness, stupor.
Disorders from the side of the organ of sight. Very rarely: miosis.
Disorders from the gastrointestinal tract. Very rarely: intestinal obstruction (including paralytic intestinal obstruction), megacolon (including toxic megacolon).
Disturbances from the skin and subcutaneous tissues. Very rarely: angioedema, bullous rash, including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme, pruritus, urticaria.
Disorders from the kidneys and urinary tract. Very rarely: retention of urine.
General disorders. Very rarely: fatigue.